Roth Capital Rates Castle Biosciences (CSTL) buy
Roth Capital continues to recommend buying Castle Biosciences with a $40 price target, a 64.61% upside from the current price.
Reviewed by automated data checks against the source data. How we make and check alerts
Roth Capital rated Castle Biosciences, Inc. ($CSTL) "buy" with a $40 price target on June 25, 2026.
Since the rating, $CSTL is up 5.2% after 1 week, up 6.7% after 1 month and up 39.5% to date (from the $22.91 close on Jun 25, 2026).
CSTL
Castle Biosciences, Inc.
Key Points
- Roth Capital reiterated its buy rating for Castle Biosciences, Inc. (CSTL) on June 25, 2026, with a $40 price target.
- Roth Capital's $40 price target implies 64.61% upside from Castle Biosciences, Inc.'s ($CSTL) current $24.30 share price.
- Shares of Castle Biosciences were trading at $22.12 on Thursday, with a market cap of $643 million and a 52-week range of $14.59 to $44.28.
- Insider transactions included multiple sales by CEO Derek Maetzold and COO Kristen Oelschlager in June 2026.
Get $CSTL trade alerts by text
We text you when insiders, Congress or big funds trade $CSTL. Free.
Not investment advice. EarningsIQ is not a registered investment adviser, and this automated Castle Biosciences, Inc. alert may contain errors. Disclosures
Castle Biosciences, Inc. (NasdaqGM: CSTL) received a vote of confidence from Roth Capital on June 25, 2026. The firm reiterated its buy rating on the stock, setting a price target of $40. This comes as shares traded at $22.12 on Thursday.
Roth Capital vs. the S&P 500
Hypothetical returns from Roth Capital's disclosed trades, not real profit or advice. How we model this.
Castle Biosciences, Inc. Stock Down 28.1%
Shares of Castle Biosciences, Inc. traded near $22.12 on Thursday. The company has a market cap of approximately $643 million. It operates with a forward P/E ratio that is not meaningful due to its lack of profitability. The stock's beta is 1.023, indicating slightly more volatility than the market. Over the past year, the stock has seen a low of $14.59 and a high of $44.28. Its 50-day moving average is $21.92, while the 200-day moving average stands at $28.71. The company maintains a strong liquidity position with a current ratio of 6.75 and a quick ratio of 6.26.
$CSTL price target
Castle Biosciences, Inc. daily closes and this analyst's $40 target. Not advice.
Recent Earnings
Castle Biosciences reported revenue of $339.9 million, although it faced a slight decline with a revenue growth rate of -4.9%. The company is not currently profitable, with a net margin of -3.78% and a return on equity of -2.85%. Investors should mark August 3, 2026, on their calendars for the company's next earnings announcement.
Insider Buying and Selling at Castle Biosciences, Inc.
In June 2026, insider activity at Castle Biosciences included several transactions. CEO Derek Maetzold sold 4,172 shares at an average price of $20.66 on June 15 under a planned sale, while also buying 550 shares at $2.39. He made additional sales of 6,214 shares on June 1. COO Kristen Oelschlager sold 8,587 shares at $20.71 on June 16 under a Rule 10b5-1 plan.
Analysts Set New Price Targets
On June 25, 2026, Roth Capital reiterated its buy rating for Castle Biosciences with a $40 price target. BTIG also maintained a buy rating with a $40 target on May 13, 2026. Baird reiterated its buy rating on May 7, with a slightly higher target of $43. The consensus among analysts is a buy rating, with an average target price of $44 based on eight opinions.
About Castle Biosciences
Castle Biosciences, Inc. is a molecular diagnostics company based in Friendswood, Texas. It provides test solutions for dermatologic cancers, Barrett's esophagus, atopic dermatitis, and uveal melanoma. The company offers various gene expression profile tests that help predict the risk of cancer metastasis and guide treatment decisions. Led by CEO Derek J. Maetzold, Castle Biosciences serves the dermatology and gastroenterology markets.
Bottom Line
Roth Capital's reiteration of a buy rating for Castle Biosciences underscores confidence in the company's potential, despite current financial challenges. Investors should note that analyst ratings and price targets can influence stock performance, but are not guarantees. As always, 13F filings and analyst reports reflect past analyses and may not indicate future performance.
Related Filing Alerts
Source: Roth Capital's rating change on $CSTL (Jun 25, 2026). Written by software, not financial advice. How we make alerts